Education
About Us
Working with TipRanks
Follow Us
Nova Eye Medical (AU:EYE)
ASX:EYE
EYE Stock Chart & Stats
AU$0.13
-AU$0.01(-5.26%)
At close: 4:00 PM EST
AU$0.13
-AU$0.01(-5.26%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.21
Previous CloseN/A
Volume155.74K
Average Volume (3M)204.72K
Market Cap
AU$45.57M
Enterprise ValueAU$43.54M
Total Cash (Recent Filing)AU$5.05M
Total Debt (Recent Filing)AU$3.02M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding284,833,280
10 Day Avg. Volume176,528
30 Day Avg. Volume204,722
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Product PortfolioNova Eye's focus on surgical devices and consumables positions it in a specialized, procedure-driven market where products are consumed repeatedly and are integral to clinical workflows. This creates durable, recurring demand and strengthens long-term customer relationships and product stickiness.
Low Financial LeverageA low debt-to-equity ratio provides financial flexibility to fund R&D, manufacturing scale-up, and commercialization without heavy interest burdens. In capital-intensive medtech, manageable leverage reduces default risk and supports strategic investment during multi-year product cycles.
Sustained Revenue GrowthConsistent top-line growth demonstrates market acceptance and increasing adoption of products. A growing revenue base supports operating scale and provides a platform to invest in margin recovery, distribution expansion, and new product development over the medium term.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate ongoing cash burn that limits reinvestment and forces dependence on external financing or equity dilution. Over months this constrains ability to scale manufacturing, commercialize new products, and sustain operations without funding.
Sharply Declining Gross MarginA large fall in gross margin signals rising cost of goods sold, adverse mix, or pricing pressure. Margin compression reduces operating leverage, making profitability harder to achieve and undermining free cash flow recovery unless cost structure or pricing is corrected.
Ongoing Losses And Negative ROEContinued net losses and negative return on equity mean the company is not generating shareholder returns and is consuming capital. Without a clear, sustained path to profitability, the business may face prolonged funding needs and weaker capacity to invest in strategic growth initiatives.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.09 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$45.57M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 27, 2026 which is in 182 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -AU$0.012 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.007.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,833,280 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.012 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EYE Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $7.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-44.16%
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical (EYE) is a medical technology company focused on developing innovative solutions for the diagnosis and treatment of eye diseases. Operating primarily in the ophthalmology sector, Nova Eye Medical specializes in advanced surgical devices, including their proprietary iTrack system for treating glaucoma and various retinal surgeries. The company aims to enhance the quality of eye care through its cutting-edge products, which are designed to improve patient outcomes and streamline surgical procedures.
Technical Analysis
Compumedics Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
Options Prices
Currently, No data available
---